Roche's Vabysmo Lifts Vision By 4.6 Letters In Untreated nAMD Eyes And 8.2 In DME After 12 Months In Real-World VOYAGER Data Presented At EURETINA
New real-world results for Vabysmo in nAMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals1-3Advanced AI-enabled analysis of imaging
Roche's eye medicine Vabysmo helped patients see better in real-world use. When you see new medicine results, watch whether they hold up in actual patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.